Hjem › Leverkreft (hepatocellulært karcinom) › Illinois › Chicago
Kliniske studier for Leverkreft (hepatocellulært karcinom) i Chicago, IL
16 studier for Leverkreft (hepatocellulært karcinom) søker deltakere på steder i og rundt Chicago (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RekruttererFase 1
- Exelixis Clinical Site #26, Chicago
National Liver Cancer Screening Trial
RekruttererFase 4
- Northwestern University, Chicago
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
RekruttererFase 1/2
- Local Institution - 0107, Chicago
Defining the Ablative Dose for Y-90 TARE
RekruttererFase 2
- Northwestern University, Chicago
Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
RekruttererObservasjonsstudie
- RUSH University Medical Center, Chicago
- University of Chicago, Chicago
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
RekruttererFase 3
- Research Site, Chicago
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
RekruttererFase 1/2
- Lurie Children's Hospital-Chicago, Chicago
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
RekruttererFase 3
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
RekruttererFase 2
- University of Chicago Comprehensive Cancer Center, Chicago
DRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection.
RekruttererObservasjonsstudie
- Rush University Medical Center, Chicago
Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer
RekruttererFase 1/2
- Northwestern University, Chicago
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
RekruttererFase 1
- Clinical Trial Site, Chicago
Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk
RekruttererFase 2
- Northwestern University, Chicago
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
RekruttererFase 4
- University of Chicago Medical Center, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekruttererObservasjonsstudie
- Massive Bio SYNERGY-AI site, Chicago
The Dragon PLC Trial (DRAGON-PLC)
Rekrutterer
- Rush University Medical Center, Chicago
Leverkreft (hepatocellulært karcinom)-studier i andre byer
- Houston, TX31 studier
- New York City, NY24 studier
- Dallas, TX19 studier
- Los Angeles, CA19 studier
- Boston, MA18 studier
- Cleveland, OH18 studier
- Philadelphia, PA16 studier
- Pittsburgh, PA15 studier
- San Francisco, CA14 studier
- Orange, CA14 studier
- Jacksonville, FL14 studier
- San Antonio, TX13 studier
Andre studier i Chicago
- Ikke-småcellet lungekreft61 studier
- Brystkreft59 studier
- Kreft (alle typer)51 studier
- Metastatisk kreft45 studier
- Prostatakreft45 studier
- Lungekreft41 studier
- Fedme41 studier
- Eggstokkreft36 studier
- Kolorektal kreft34 studier
- Slag34 studier
- Hjertesvikt31 studier
- Overvekt29 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.